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Objective: Depressive symptoms have a high prevalence in patients with Parkinson’s
disease (PD) and are associated with cognitive dysfunction. Especially in PD with mild
cognitive impairment (MCI), a time-efficient and valid instrument for the assessment of
depression primarily focusing on psychological symptoms and disregarding confounding
somatic symptoms is needed. We performed an examination of the psychometric
properties of the Beck Depression Inventory II (BDI-II) and the Beck Depression Inventory
Fast Screen (BDI-FS).
Methods: The sample consisted of 64 patients [22 females and 42 males, mean age:
67.27 years (SD = 7.32)]. Depressive symptoms were measured in a cohort of PD
patients with MCI. For the BDI-II and BDI-FS the psychometric concepts of internal
consistency, convergent validity and diagnostic agreement were assessed.
Results: Patients gave higher ratings on test items addressing somatic symptoms
than those addressing non-somatic ones. The correlation between the absolute total
scores of the BDI-II and the BDI-FS was significant (r = 0.91, p < 0.001), which
indicated convergent validity. The Cronbach’s alpha values indicated adequate internal
consistencies for both measures (BDI-II: 0.84; BDI-FS: 0.78). There was a higher than
chance level agreement of diagnoses of the two questionnaires, measured by Cohen’s
kappa (0.58, p < 0.001). The agreements between previous diagnosis of depression
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and the diagnoses of the BDI-II/BDI-FS were also significantly higher than chance level
(BDI-II: 0.34, p = 0.007, BDI-FS: 0.39, p = 0.002). Additional AUC analysis across
different cutoffs showed that performance of BDI-FS was better than BDI-II, supporting
the observation of an equivalent or better performance of BDI-FS than BDI-II. Importantly,
AUC analysis confirmed that a cutoff = 4 for BDI-FS was suitable in the considered
sample of patients with PD-MCI.
Discussion: In a cohort of PD-MCI, the BDI-FS demonstrates adequate psychometric
properties in comparison to the BDI-II and can be used as a screening measure
for assessing depression in cognitively impaired PD patients, focusing solely on
psychological symptoms. Still, further research is needed to validate this instrument.
Keywords: Parkinson’s disease, depression, mild cognitive impairment, BDI-FS, BDI-II
INTRODUCTION
Parkinson’s disease (PD) is primarily known to bear motor
symptoms such as tremor, bradykinesia, rigidity, and postural
instability (1). However, not only motor symptoms play a role in
PD, there is also a high prevalence of non-motor symptoms such
as depression (2). A depressive condition in PD has substantial
clinical relevance and a high impact on patients’ quality of life
(3). Thus, efficient and accurate instruments for the diagnosis of
depressive symptoms in PD for clinical practice are of utmost
importance. Furthermore, as previously described by other
studies, an association exists between depression and cognitive
dysfunction. Mild cognitive impairment (MCI) and dementia
occur frequently in PD patients, and the presence of MCI
increases the risk of developing a fully pronounced dementia
(1, 4). The Global Parkinson’s Disease Survey demonstrated
that depression is the most important predictor for cognitive
dysfunction in PD (5). This finding emphasizes the relevance of
efficient detection of depression in PD with MCI, especially for
avoiding further decompensation of the cognitive impairment.
A commonly implemented test for the assessment of
depression is the Beck Depression Inventory, which is currently
available in a revised second version (BDI-II) (6). The test was
shown to have adequate diagnostic properties in PD samples
(7–9). Nevertheless, there are several aspects about the BDI-II
that may be detrimental for screening, especially in outpatient
or primary care settings. First, it is extensive and its length can
be shortened for the sake of time efficiency and less cognitive
demand. Second, and most importantly in patient populations
such as PD, the use of items addressing somatic symptoms
can be confounded by symptoms that are caused purely by
PD and not by a depressive condition, thus resulting in false
positive diagnoses (10, 11). When scrutinized in detail, somatic
items from the BDI-II such as for example Loss of Energy,
Changes in Sleeping Pattern, Changes in Appetite, or Tiredness
or Fatigue can represent a PD symptom and not depict an
underlying depression.
As an alternative measure with regard to the aforementioned
issues, Beck et al. proposed the Beck Depression Scale Fast
Screen (BDI-FS) (12). It contains seven items from the BDI-II
that exclusively address psychological symptoms and was
designed specifically for implementation in patients with somatic
medical conditions. Previous research demonstrated adequate
psychometric properties in various diseases, such as multiple
sclerosis, end-stage renal disease, pain syndrome, and stroke (13–
16). The psychometric properties in PD samples have not yet
been investigated.
The aim of the present study was to assess the psychometric
properties of the BDI-FS in a sample of PD patients with MCI.
The following aspects were investigated:
- Internal consistency of the BDI-FS as a measure of reliability
- Convergent validity by measuring the correlation between the
BDI-FS and the BDI-II
- Diagnostic validity by comparing scoring above a defined
cutoff indicating a clinical condition for major depression via
BDI-FS and BDI-II
- Diagnostic validity by comparing the scoring above a defined
cutoff indicating a clinical condition for major depression via
BDI-FS diagnosis and current clinical diagnosis of depression
according to the ICD-10 (17).
METHODS
Sample
The data used here was taken from the multicentric study
“Training Parkinson Patients’ Cognition” (TrainParC, German
Registry for Clinical Studies no. 00010186), involving the
university hospitals of Düsseldorf, Cologne, Kiel, and Tübingen.
The conduction was approved by the ethics committee of all
involved universities.
Sixty-four patients were included into the study. Main
inclusion and exclusion criteria as well as the MDS specific
guidelines for PD-MCI level I and level II categories (18) are
listed in Table 1.
Furthermore, patients were also classified according to the
stages of PD by Hoehn and Yahr (19). For detailed information
regarding the main study please refer to Kalbe et al. (20).
Tests and Further Assessments
BDI-II
The German version of the BDI-II (6, 21) was used to assess
depressive symptoms. It consists of 21 items, each of which
is rated on a 4-point Likert scale. The point value of a single
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TABLE 1 | Inclusion and exclusion criteria, MDS specific guidelines for PD-MCI level I and level II categories and neuropsychological test results of the study sample.
Inclusion criteria Exclusion criteria
(i) Age between 50 and 85 years (i) Clinical PDD diagnosis or outcomes in the Pill-Questionnaire
indicating caregiver dependency
(ii) PD diagnosis according to the UK Brain Bank Criteria (ii) Depression (operationalized with Beck Depression Inventory II ≥20
points)
(iii) Self-reported cognitive impairment assessed with the Subjective Cognitive Impairment
questionnaire and/or objective cognitive impairment assessed with the Montreal Cognitive
Assessment <26 points
(iii) Acute suicide tendency
(iv) PD-MCI according to Movement Disorders Society (MDS) task force Level-II criteria (iv) Severe comorbidities affecting life expectancy, medication, or
quality of life
(v) At least 1 year since PD diagnosis (v) Severe fatigue
(vi) Stable medication within 4 weeks before screening (vi) Prominent impulse control disorder or dopamine dysregulation
syndrome
(vii) Written informed consent (vii) Acute psychosis or psychotic episode in the last 6 months before
study participation
(viii) Dementia medication
(ix) Participation in other treatment studies within the last 2 months
before study participation
(x) Deep brain stimulation
(xi) Pregnancy or nursing period
MDS specific guidelines for PD-MCI
level I and level II categories
Neuropsychological test results of the study sample
A. Level I (abbreviated assessment) Attention M SD
• Impairment on a scale of global cognitive
abilities validated for use in PD or
d2-R concentration performance −1.55 1.01
d2-R errors −0.37 1.335
• Impairment on at least two tests, when a
limited battery of neuropsychological tests
is performed (i.e., the battery includes less
than two tests within each of the five
cognitive domains, or less than five
cognitive domains are assessed)
Working memory
Letter-number sequencing 0.095 0.895
Digit span backwards −0.23 1.11
B. Level II (comprehensive assessment)
• Neuropsychological testing that includes
two tests within each of the five cognitive
domains (i.e., attention and working
memory, executive, language, memory,
and visuospatial)
• Impairment on at least two
neuropsychological tests, represented by
either two impaired tests in one cognitive
domain or one impaired test in two
different cognitive domains
• Impairment on neuropsychological tests
may be demonstrated by: Performance ∼
1–2 SDs below appropriate norms or
Significant decline demonstrated on serial
cognitive testing or Significant decline
from estimated premorbid levels
Executive functions
Semantic word fluency 0.415 1.16
Phonemic word fluency 0.305 1.01
MCST categories −0.865 1.015
Key search—raw score 11.275 3.295
Language
Boston nming test −0.09 1.31
ACL speech comprehension—raw score 17.635 1.155
Memory
CVLT learning performance −1.19 1.25
CVLT long delay free recall −1.215 1.105
ROCFT delayed free recall 0.19 1.06
Visuocognition/visuospatial
ROCFT figure copy 0.24 1.44
Bnton judgement of line orientation −0.615 1.405
Data of the baseline neuropsychological test results presented as mean standardized z-scores or raw scores and standard deviations, with higher values indicating better performance.
MCST, Modified Wisconsin Card Sorting Test; ACL, Aphasia Check List; CVLT, California Verbal Learning Test; ROCFT, Rey-Osterrieth Complex Figure Test.
item ranges from zero to three points. The items represent the
symptoms of a depressive episode defined by the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV) (22). Higher scores indicate more severe symptoms, scores of
14 and above indicate at least a mild condition, and a maximum
of 63 points can be achieved (6).
BDI-FS
The BDI-FS (12, 23) is a shortened version of the BDI-II
consisting of 7 items, including Sadness, Pessimism, Past Failure,
Loss of Pleasure, Self-Dislike, Self-Criticalness, and Suicidal
Ideation. The item format is identical to that of the long version.
Again, higher scores indicate a more severe condition with four
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being the cutoff for clinical significance. The maximum score
obtained on the BDI-FS is 21 points. The BDI-FS sum score was
obtained by adding the item scores of the respective BDI-II items.
Medical History of Depression
Participants were questioned concerning previous medical
diagnosis of depression and whether it was still present or in
remission. Medical professionals in Germany are obliged to pose
diagnoses based on the criteria described in the International
Classification System of Diseases, Version 10 (ICD-10) (24).
Statistical Analysis
The total scores of the BDI-II and the BDI-FS were correlated
by use of Spearman correlations. Cronbach’s alpha index was
calculated to assesses the internal consistency of the two
measures. The diagnoses were compared by implementing
a Cohen’s kappa, which indicates the diagnostic agreement
between the two tests. Then, the BDI-II and the BDI-FS and
clinical diagnoses were compared to the presence of a diagnosis of
depression in the patients’ anamnesis. P-values below 0.05 were
considered significant. All calculations were performed using
IBM SPSS Statistics, Version 22.0 (25).
AUC Analysis
In order to gain further insight into sensitivity and specificity
characteristics as well as performance of BDI-FS and BDI-II
across a range of cutoffs, receiving operator curves (ROC) on the
basis of a logistic regression model (dependent variable: clinical
diagnosis of depression; independent variable: BDI-FS or BDI-
II score classification for a given cutoff) and “area under ROC”
(AUC) were calculated by using MATLAB 8.5, The Mathworks,
Inc., Massachusetts, US. Note that AUC quantifies how much
a test score for a given cutoff is able to distinguish between
depression and non-depression state in a subject. AUC ranges
in value from 0 and 1. A test score whose predictions are 100%
correct has an AUC of 1.0, whereas a value of 0.5 for AUC
indicates that the test score has no discriminatory ability.
RESULTS
The sample consisted of 64 patients [22 female and 42male, mean
age: 67.27 years (SD = 7.32)], with an average of 13.70 years of
education (SD = 3.37). The mean age at PD onset was 58.33 (SD
= 11.40). Eight patients were in Hoehn & Yahr stage 1, 40 in stage
2, 15 in stage 3 and one in stage 4. The descriptive statistics for the
scores of both questionnaires are presented in Table 2.
TABLE 2 | Descriptive statistics of the BDI-II and BDI-FS.
Statistics BDI-II BDI-FS
Kolmogorov-Smirnov test 0.170 >0.000
Mean 8.84 2.06
Standard deviation 5.03 2.12
Median 8 2
Range (minimum and maximum value) 0–19 0–8
The correlation between the total scores of the BDI-II and the
BDI-FS was 0.87 (p< 0.001). Cronbach’s alpha for the BDI-II was
0.73 and 0.71 for the BDI-FS. The agreement of diagnoses of the
two questionnaires, measured by Cohen’s kappa, was significant
with a value of 0.59 (87%, p < 0.001). The agreement between
a current diagnosis of depression in the medical history and the
diagnosis of the BDI-II was significantly higher than chance with
a Cohen’s kappa of 0.34 (81%, p= 0.007). The BDI-FS also agreed
significantly more often than chance with a present diagnosis of
depression, as indicated by a significant Cohen’s kappa of 0.39
(81%, p < 0.002).
AUC analysis revealed maximum performance of BDI-FS
(AUC = 0.7222) at cutoff = 4 (Figure 1A), while for BDI-
II such performance (AUC = 0.6740) occurred at cutoff
= 15 and 16 (Figure 1B). Thus, for the addressed sample
of PD-MCI patients, BDI-FS showed better performance in
distinguishing a depression state than BDI-II at the mentioned
cutoffs (Figure 1C). Both BDI-FS and BDI-II showed better
performance than just a random selection (AUC = 0.5). In
particular, ROC of BDI-FS at cutoff= 4 revealed low “sensitivity”
[true positive rate (TPR)] and high “specificity” [1-false positive
rate (FPR)] at threshold = 0.6923 as well as high sensitivity
and low specificity at threshold = 0.1569. ROC of BDI-II at
cutoff = 15 and 16 revealed low sensitivity and high specificity
at threshold= 0.7 as well as high sensitivity and low specificity at
threshold= 0.1852.
DISCUSSION
The present study aimed to define the psychometric properties
of the BDI-FS in a PD-MCI population. Our results indicate
adequate psychometric properties. The BDI-FS strongly
correlates with the BDI-II. It shows an adequate internal
consistency, while the BDI-II has a slightly better value (26).
The agreement between both measures is significantly higher
than chance with a value that can be classified as moderate (26).
The agreements of the BDI-II and the BDI-FS with a present
diagnosis of depression as indicated by the patient’s history can
both be classified as fair according to the common norm—the
value of the BDI-FS even being slightly larger (27).
One of the most obvious positive characteristics of the BDI-
FS is its brevity. Neitzer et al. found that those patients who
did not complete the whole BDI-II assessment were significantly
older (15). Regarding the rather high mean age of PD patients
and potential deficits in language processing, the screening
for depression should be kept at a minimum length (26, 28).
With a short questionnaire, the resulting validity would not be
compromised due to neuropsychological or motivational aspects.
As indicated by the high correlation between the two measures,
the BDI-FS is an acceptable alternative if time or cognitive
resources are a relevant issue.
AUC analysis across different cutoffs showed that
performance of BDI-FS was better than BDI-II, thus supporting
the observation of an equivalent or better performance of BDI-FS
than BDI-II for the considered sample of PD-MCI patients. The
fact that BDI-II presented highest performance at cutoffs 15 and
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FIGURE 1 | “Area under ROC” (AUC) analysis. (A) AUC of ROC corresponding to BDI-FS across different cutoffs: 0–9. It is noticeable that highest performance is
achieved at cutoff = 4; (B) AUC of ROC corresponding to BDI-FS across different cutoffs: 0–20. It is noticeable that highest performance is achieved at cutoff = 15
and 16; (C) ROC of BDI-FS (cutoff = 4) corresponding to logistic regression model: depression-state = 2.4927*BDI-FS −1.6818, p < 0.001 (coefficient and intercept)
and ROC of BDI-II (cutoff = 15 and 16) corresponding to logistic regression model: depression-state = 2.3289*BDI-II −1.4816, p = 0.0026 (coefficient), p < 0.001
(intercept). For the considered sample of PD-MCI patients, better performance of BDI-FS than BDI-II was revealed.
16 is consistent with previous criteria (cutoff >14) as reported in
the case of mild condition of depression (6). Importantly, AUC
analysis confirmed that a cutoff = 4 for BDI-FS was suitable in
the considered sample of patients with PD-MCI.
The BDI-FS deliberately omits the use of somatic items to
avoid confounding effects by overlapping symptoms that may
stem from a somatic disease rather than depression itself (12).
Regarding the spectrum of possible non-motor symptoms in
PD, there is a multitude of symptoms that can also count as a
somatic symptom of depression, e.g., insomnia, gastrointestinal
problems, sexual dysfunction or fatigue (10, 29). In our sample,
the items with the highest mean scores were Changes in Sleeping,
Concentration Difficulties, Tiredness or Fatigue, and Loss of
Energy. Overall, as Figure 2 shows, the items addressing somatic
symptoms, which can be found in the second half of the
questionnaire, mostly scored higher than those addressing non-
somatic items. This suggests that somatic symptoms can lead
to false positive results when the full version of the BDI-II
is implemented.
For the purpose of this study, we calculated the BDI-FS
score by adding the item scores of the respective BDI-II items.
Thus, we cannot guarantee the same results if the patients
would have received the BDI-FS as a separate questionnaire.
Effects regarding item order and questionnaire length might be
a relevant factor. Future studies should take this into account and
consider applying the BDI-FS separately.
One potential limitation of the present study is the selectivity
of the sample. Whether the results can be transferred to a general
PD population, which also includes cognitively unimpaired
or demented patients, remains to be scrutinized by future
studies. Further research is required to clarify the psychometric
properties of the BDI-FS in other, possibly broader PD samples.
Furthermore, a moderate or more severe degree of depression
was one of the exclusion criteria for the main study in order
to prevent interactions between cognitive performance and
psychopathology. Therefore, our results can only be transferred
to milder forms of depressive states. The psychometric
properties in more severe depressed patients are yet to
be reviewed.
Furthermore, patients with PD may present somatic
symptoms that are not caused by depression, but they may
present prototypical somatic symptoms of depression. Not
exploring these symptoms could cover up depressive symptoms
present in patients, possibly leading to false negative results.
Additional analysis of positive and negative predictive value
should be addressed by further research.
Even with regard to the overall adequate psychometric
properties of the BDI-FS and the BDI-II in PD, it is important
to emphasize that their use is appropriate for screening purposes
only. If a secure diagnosis is required, neither of the two
questionnaires can replace a complete diagnostic procedure.
The diagnostic criteria should always be confirmed by a
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FIGURE 2 | Mean item score values for all items of the BDI-II. The x-axis represents the 21 items of the BDI-II and the 7 BDI-FS items Sadness, Pessimism, Past
Failure, Loss of Pleasure, Self-Dislike, Self-Criticalness, and Suicidal Ideation (dark columns). The y-axis depicts the mean scores (and standard deviation) on the
individual items with scores ranging from 0 to 3. The items in the second half of the questionnaire address somatic symptoms and mostly received higher scores in
our sample than the non-somatic items of the first half.
trained clinician in a (semi) structured interview to ensure
no confounding effect of possible cognitive or somatic biases,
to which depressed patients are particularly prone (30). In
the present study, the diagnoses of depression that were
used for calculation of the diagnostic validity of the BDI-FS
were derived from the patients’ medical histories and reports,
but no clinical (semi) structured interview was performed.
Furthermore, we compared the diagnosis resulting from the
assessment by BDI-II or BDI-FS with previous diagnosis of
depression in the medical history. As mentioned above, in
Germany such a diagnosis is usually based on the criteria posed
by the ICD-10 rather than the DSM-V. The questionnaires
used are based on the latter. Although both ICD-10 and
DSM-V mostly rely on the same symptoms for the diagnosis
of a depressive state, the criteria are not identical and the
descriptions differ in wording. These factors could account for
the relatively low agreement values with the questionnaires, as
we cannot guarantee for the validity of these diagnoses. To
ensure maximum validity of the diagnostic criterion, future
studies should include an assessment of depressive symptoms
based on the DSM-V by a trained clinician as part of
the procedure.
Finally, to establish possible advantages or disadvantages of
the BDI-FS, it can be compared to other frequently administered
depression scales. For instance, one test constructed for use in
similar populations as the one examined in the present study is
the Geriatric Depression Scale (31). One possible aspect for future
studies could lie on comparing its psychometric values to those of
the BDI-FS, especially with regard to the different item formats
(dichotomous vs. Likert scale).
In summary, the BDI-FS shows satisfactory reliability, as well
as validity as demonstrated by the correlation and agreement
with the full version of the BDI-II. The agreement rates with
a current diagnosis of depression are acceptable, although the
diagnosis was not assessed as part of the study. A diagnostic
interview should be included in future studies of the BDI-
FS in PD, preferably in samples of various cognitive statuses.
Although the BDI-FS cannot replace a complete diagnostic
procedure, it may be used as a shorter alternative to the BDI-II
in contexts where time efficiency, somatic symptomatology, and
minimum cognitive load are relevant, such as in primary care or
outpatient settings.
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